Multiple
Successful Exits

Shifamed has a history of entrepreneurial success founding cutting
edge medical technology companies and bringing highly-valued
products to market, either direct or through an acquisition.

We have the experience, knowledge, and a demonstrated ability to discern new technologies that represent compelling business opportunities and structure deals, which provide meaningful returns for our investors.

Currently, Shifamed is busy working on several companies that range in development phase from stealth mode and early stage design to commercial release and next generation work. For more information on our portfolio companies, see below or contact them directly.

Current Portfolio Companies

Atia Vision focuses on the development of an accommodating intraocular lens for the ophthalmology market.

Nuvera Medical is focused on developing a novel imaging platform for use in a growing number of complex cardiovascular procedures.

Supira Medical is focused on the development of a next generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures.

Legacy Portfolio Companies

Apama Medical, an atrial fibrillation ablation company, was sold in 2017 to Boston Scientific for $175 million in cash up-front, with up to $125 million in milestone payments.

SOLD IN 2017

Kalila Medical, a company that provides catheters to address the myriad of delivery and access challenges seen in complex electrophysiology procedures and vascular interventions, was sold to Abbott in 2016 for an undisclosed amount.

SOLD IN 2016

Maya Medical, a renal denervation company, was sold in 2012 to Covidien for $60 million in cash up-front, with up to $170 million in milestone payments.

SOLD IN 2012

Sadra Medical, a percutaneous aortic valve replacement company, was sold in 2011 to Boston Scientific for $225 million in cash up-front, with up to $225 million in milestone payments.

SOLD IN 2011

Embolic Protection, Inc. (EPI), an intravascular filter company, was sold to Boston Scientific in 2001 for $75 million in cash up-front, with an undisclosed amount in milestone payments.

SOLD IN 2001